Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Assets (2023 - 2025)

Contineum Therapeutics has reported Current Assets over the past 3 years, most recently at $184.9 million for Q3 2025.

  • Quarterly results put Current Assets at $184.9 million for Q3 2025, down 14.04% from a year ago — trailing twelve months through Sep 2025 was $184.9 million (down 14.04% YoY), and the annual figure for FY2024 was $206.4 million, up 61.61%.
  • Current Assets for Q3 2025 was $184.9 million at Contineum Therapeutics, up from $176.8 million in the prior quarter.
  • Over the last five years, Current Assets for CTNM hit a ceiling of $220.3 million in Q2 2024 and a floor of $119.7 million in Q1 2024.
  • Median Current Assets over the past 3 years was $188.5 million (2025), compared with a mean of $180.4 million.
  • Biggest five-year swings in Current Assets: soared 61.61% in 2024 and later fell 19.74% in 2025.
  • Contineum Therapeutics' Current Assets stood at $127.7 million in 2023, then soared by 61.61% to $206.4 million in 2024, then decreased by 10.4% to $184.9 million in 2025.
  • The last three reported values for Current Assets were $184.9 million (Q3 2025), $176.8 million (Q2 2025), and $192.1 million (Q1 2025) per Business Quant data.